`A. Personal Information
`Name in Full
`Business Address
`
`Business Phone
`Home Address
`
`Place of Birth
`Citizenship
`E-Mail Address
`
`
`B. Education
`College or University
`
`
`Medical School
`
`Internship
`
`Residency
`
`Fellowship
`
`
`
`Honors and Awards
`
`CURRICULUM VITAE
`
`Thomas D. Coates, M.D.
`Children’s Hospital Los Angeles
`Division of Hematology-Oncology
`4650 Sunset Boulevard, MS 54
`Los Angeles, CA 90027
`(323) 361-2352
`1311 Rossmoyne Avenue
`Glendale, CA 91207
`Bay City, MI
`U.S.A.
`tcoates@chla.usc.edu
`
`College, Saginaw, MI, A.S., 1969
`University of Michigan, Ann Arbor, MI, B.S.
`(Physics), 1971
`University of Michigan School of Medicine,
`Ann Arbor, MI, M.D., 1975
`James Whitcomb Riley Hospital for Children
`(Pediatrics), Indianapolis, IN, 1975 –
`1976
`James Whitcomb Riley Hospital for Children
`(Pediatrics), Indianapolis, IN, 1976 –
`1978
`James Whitcomb Riley Hospital for Children
`(Pediatric Hematology-Oncology,
`Clinical Appointment), Indianapolis,
`IN, 1978 – 1979
`James Whitcomb Riley Hospital for Children,
`(Pediatric Hematology-Oncology,
`Research Appointment), Indiana
`University School, Indianapolis, IN,
`1979 – 1982
`President, Phi Theta Kappa Junior College
`Honorary
`
`Apotex Tech.
`Ex. 2002
`
`

`

`
`
`
`
`
`
`
`Licensure
`
`Board Certification
`
`
`
`Other
`
`
`
`Sigma Xi Research Honorary
`National Research Service Award,
`July 1979 – July 1982
`American Cancer Society Junior Faculty
`Clinical Contract, No JFCF702B, July
`1982 – June 1986
`H. Russell Smith Award for Innovation in
`Pediatric Biomedical Research
`July 14, 2009
`27995, Indiana, 1976
`G56123, California, 1986
`American Board of Medical Examiners, 1976
`American Board of Pediatrics, 1980 (#24947)
`American Board of Pediatrics Sub/Board of
`Hematology-Oncology, 1982 (#582)
`Certified Investigator by Committee on
`Clinical Investigation (IRB: M-118-
`O2NR) 10/24/05
`
`
`
`C. Professional Background
`Academic appointments
`Assistant Scientist and Part-time Assistant Professor, Division of Pediatric
`Hematology-Oncology, James Whitcomb Riley Hospital for Children, Indiana
`University School of Medicine, Indianapolis, IN 1982 – 1985.
`Assistant Professor of Pediatrics, James Whitcomb Riley, Indiana University
`School of Medicine, Indianapolis, IN 05/85 – 08/85.
`Assistant Professor of Pediatrics, USC School of Medicine, Los Angeles, CA.,
`University of Southern California, 09/85 – 06/92.
`Associate Professor of Pediatrics (with tenure), USC School of Medicine, Los
`Angeles, CA 07/92 – present.
`Associate Professor of Pathology, USC School of Medicine, Los Angeles, CA.,
`University of Southern California, 02/96 – 01/05.
`Professor of Pediatrics and Pathology (with tenure), 2/05, USC School of
`Medicine, Los Angeles, CA., University of Southern California 06/92 – present.
`Clinical Administrative Appointments
`Attending Physician, Children’s Hospital Los Angeles, Division of Pediatrics,
`Department of Hematology and Oncology, Los Angeles, CA 1985 – Present.
`
`

`

`Specific teaching responsibilities
`Indiana University
`Clinical Lecturer Senior Elective in Hematology Clinic Indiana University School
`of Medicine
`Lecturer, Pediatric Graduate Course, Indiana University School of Medicine
`University of Southern California-Keck School of Medicine
`Teach medical students and residents in wards and clinics
`Lecture to various groups within the University and in continuing educational
`program on clinical and research topics
`Mentor fellows in clinical Hematology-Oncology
`Thesis advisor to graduate students. Mentor to post-doctoral fellows in the
`research laboratory
`University of Southern California
`Lecturer to medical students “Neutrophil Function and disorders”
`Supervise graduate students, Department of Pathology graduate program
`Supervise graduate students, Department of Biomedical Engineering
`Teach Pediatric Residents on wards and in Clinic
`Specific Administrative Responsibilities
`Director, White Cell Function Laboratory, Department of Pathology, Children’s
`Hospital Los Angeles, September 1985 – June 1992
`Section Head of Hematology-Division of Pediatric Hematology-Oncology,
`Children’s Hospital Los Angeles, Los Angeles, CA July 1991 – present
`Director, Bone Marrow Laboratory, Division of Pediatric Hematology, Children’s
`Hospital Los Angeles, Los Angeles, CA July 1992 – July 2010
`Director of Medical Informatics, Department of Information Services, Children’s
`Hospital Los Angeles, Los Angeles, CA August 1993 – August 2001
`Director, Red Cell Defects and Hemoglobinopathy Program, Children’s Hospital
`Los Angeles, Los Angeles, CA April 1995 – present
`Director, Computerized Database Management and Analysis System (CDMAS),
`for the CHLA General Clinical Research Center (GCRC) April 1995 –
`December 2007
`Medical Director, Comprehensive Hemophilia Treatment Center, Children’s
`Hospital Los Angeles, Los Angeles, CA, July 1997 – August 2001
`Director Image Analysis and Confocal Microscopy Core Facility, Children’s
`Hospital Los Angeles Research Institute, July 1, 1999 – December 2007
`
`
`
`

`

`Deferred
`
`Military Service
`Community Service
`Advisory Board, California Cooley’s Anemia Foundation Southern California July
`1, 1999 – 2009
`Advisory Board, Sickle Cell Foundation of California 8/1/1997 – 2009
`Advisory Board, Sickle Cell Institute of Los Angeles 2/1/2000 – 6/1/2003
`Medical Advisory Board, Cooley’s Anemia Foundation National, 8/1/2007 –
`Present
`D. Society Memberships
`Local
`
`Los Angeles Pediatric Society
`Microscopy Society of California
`National
`American Society of Pediatric Hematology-Oncology
`American Society of Hematology
`The Society for Pediatric Research
`European Hematology Association
`American Pediatrics Society 2010
`Consultantships
`Iron Overload in β Thalassemia and sickle cell disease: A Multi-center Study:
`RO1 DK057778-01 (Steering Committee) 1/2001 – 2005.
`Sickle cell and Neupogen safety, 2003, Amgen, Thousand Oaks CA.
`Iron overload and sickle cell disease, Novartis, Berkley CA 6/23/2003.
`Thios Pharmaceuticals, Role of anti-PSGL1 in treatment of acute chest
`syndrome. April 2004 – 2005.
`ICL 670 in Sickle Cell Disease, Novartis, May 9, 2005.
`Improving Transfusion Outcomes conference, Washington DC, June 11, 2005.
`Iron overload and cardiac iron, ApoPharma, September, 2007.
`ApoPharma, iron overload in thalassemia and sickle cell disease, 12/2008
`Consultant Novartis 8/2003, 11/04, 5/2005.
`Consultant BMF 12/2003.
`Consultant Novartis Pharmaceuticals 2004 – present.
`Consultant ApoPharma 9/2007, 12/2009.
`Sangart, Blood substitutes in sickle cell disease, 2/10/2009 – present.
`Novartis Advisory Panel on MRI and LPI use in Iron Overload 1/10/2011, Paris
`France.
`ApoPharma FDA approval team. Backup presenter for Advisory Board meeting
`September, 2011.
`Chair, Apo Pharma Ferriprox Advisory Board, Los Angeles, CA, 10/20/2012.
`
`

`

`ApoPharma Consultant, Multi Center Trial “Use of deferiprone in SCD” multi
`center trial. December 7, 2012 Atlanta.
`AesRx Consultant, Aes-135 Hemoglobin P50 shifting agent. December 9, 2012,
`Atlanta.
`Bio Products Laboratory Limited, (BPL) Consultant Intravenous haptoglobin
`study. December 10, 2012, Atlanta.
`Blue Bird Bio Consultant, HGB-204 study. Clinical protocol consulting group for
`international gene therapy in thalassemia study. 2012.
`International Study committee, SHIRE pharma, SPD602 study. 2013.
`ApoPharma Neutropenia advisory committee, 2013.
`ISIS Pharma Consultant, 2015
`Celgene Pharma Consultant, 2015
`Prolong Pharma Consultant, 2015-July 2016
`Emmaus Medical Inc. Mock FDA Advisory Panel Member, 5/10/2017
`E. Service
`Professional Organizations
`National and International
`Children’s Cancer Study Group Computer Committee (Chair) 1987 – 1989.
`Children’s Cancer Study Group High Risk Leukemia Committee 1985 – 1992.
`B19 prevalence in sickle cell disease (Chair: NHLBI) 1999 – 6/30/2004.
`Member Protocol Review panel for Pediatric Hydroxyurea trials, NHLBI Nov
`2003 – present.
`Executive committee Stroke Prevention Trial (STOP II), NHLBI / University of
`Georgia.
`Steering Committee Iron Overload in β Thalassemia and sickle cell disease: A
`Multi-center Study: RO1 DK057778-01.
`Executive committee Silent Stroke Trial, NHLBI, Feb 2004 – July 1, 2005.
`Publications committee, American Society for Pediatric Hematology/Oncology
`Feb. 2004 – 2006.
`Scientific Subcommittee for Iron, American Society for Hematology, 12/2006 –
`12/2010.
`Steering Committee Thalassemia Clinical Research Network, 2006 – present.
`Executive committee for the Silent Stroke study (NHLBI) 2/2004 – 6/31/2005.
`Publications committee American Society for Pediatric Hematology Oncology,
`2/2004 – 2007.
`Medical advisory Board National Cooley’s Anemia Foundation , 12/2006 –
`present.
`Vice Chair Scientific Subcommittee on Iron and Hemoglobin, American Society
`for Hematology, 2008 – 2009.
`
`

`

`Chair Scientific Subcommittee on Iron and Hemoglobin, American Society for
`Hematology, 2009 – 2010.
`Member of the NHLBI working group on Sickle Cell Disease, Inflammation,
`Thrombosis and Vascular Injury, Bethesda, MD Oct 28, 2009.
`Protocol review committee Baby HUG (NHLBI) 11/2002 – 12/2010.
`Chair Centers for Disease Control Thalassemia Steering Committee, 1/1/2010.
`NHLBI Sickle Cell Advisory committee, 12/1/2009 – present.
`Chair of Iron and Heme Scientific Sub-committee for American Society
`Hematology, 1/2010 – 12/2010.
`Organizing Committee, Meeting of the International Hemorheology Society and
`Clinical Hemorheology Society, Istanbul, Turkey, 2012.
`Steering committee and founding member of the North American Pediatric
`Aplastic Anemia Consortium (NAPACC), May 2012 – present.
`Executive committee (elected) North American Pediatric Aplastic Anemia
`Consortium (NAPAAC) Jan 2014 – present.
`Organizing Committee, Meeting of the International Hemorheology Society and
`Clinical Hemorheology Society, Seoul, Korea, 2015.
`
`
`University/Local
`Search Committee Medical Information Systems Director, Children’s Hospital of
`Los Angeles, 1990 – 1991,
`PCAT Committee, Children’s Hospital of Los Angeles 1991 – 1993.
`Medical Information Systems Steering Committee, Children’s Hospital of Los
`Angeles 1992 – 1995.
`PC Users Advisory Committee, Children’s Hospital of Los Angeles 1992 – 1995.
`Physicians Ad Hoc Computer Committee, Children’s Hospital of Los Angeles
`1995 – present.
`Search Committee, Hemophilia Director, Children’s Hospital Los Angeles 1993 –
`1994.
`Hematology Education Committee, Children’s Hospital Los Angeles 1990 –
`present.
`Strategic Planning Task Force Committee, Children’s Hospital Los Angeles 1992
`– 1993.
`Clinical Investigation Committee, Division of Hematology/Oncology, Children’s
`Hospital Los Angeles to present 1993 – 1995.
`Division of Hematology/Oncology, Computer Committee, (Chairman) until 1996.
`Fellowship Committee, Division of Hematology/Oncology 1994 – present.
`Ambulatory Tower Advisory Committee 9/1991 – 9/1992.
`Technology Task Force for Children’s Hospital Los Angeles 11/1991 – 11/1992.
`
`

`

`Fellow's Research Advisory Committee, Division of Hematology/Oncology, 1991
`– present.
`TDS Executive Steering Committee, Children’s Hospital Los Angeles, 3/1992 –
`3/1997.
`Children’s Cancer Study Group Data Communications Committee, Vice Chair
`11/92/3/1995 – 11/1996.
`Medical Information Systems Steering Committee, Children’s Hospital of Los
`Angeles, 8/1992 – 8/1997.
`Norris Cancer Center Clinical Database Committee 6/1993 – 8/1993.
`Data/Communication Committee: Division of Hematology 6/1993 – 6/1995.
`MAP Committee, CHLA 6/1993 – 6/1994.
`CHLA Pediatric Outcomes research committee 6/1995 – 6/1997.
`General Clinical Research Center Advisory Committee, CHLA 6/1995 – Present.
`Hospital Cost Steering committee, 10/1995 – 11/1996.
`Ancillary Services Committee, 10/1995 – 10/1996.
`Medical Group Ambulatory Committee 2/1996 – 2/1997.
`Oncology Task Force 2/1995 – 1/1996.
`Ancillary services Committee, CHLA. 1/1996 – 1/1997.
`Division of Hematology/Oncology Executive Committee 7/1997 – present.
`Medical Group Quality Assurance Committee 1/1996.
`Faculty Informatics Committee (Chair) CHLA 9/1996 – 9/1998.
`Performance Improvement Committee CHLA 9/1997.
`Chief Information Officer Search Committee 4/1998 – 5/1998.
`Chair Selection Committee Confocal Microscope, CHLA Research Institute 1998
`– 1999.
`I.S. Steering Committee, 8/1999 – 2002.
`Children’s Hospital Los Angeles Research Institute IT task force. 12/2003.
`Board of Directors Medical Information Systems Physicians’ Association, Inc
`(MISPA) 1995 – 2000.
`Physicians IS Taskforce, 1/2000 – 2002.
`Editorships and Editorial Boards:
`ASSOCIATE EDITOR, Blood Journal. 8/2016 - present
`Journal Reviews
`American Journal of Clinical Nutrition
`Cell Motility and Cytoskeleton
`Journal of Leukocyte Biology
`Blood
`Life Sciences
`
`

`

`The Journal of Biological Chemistry
`Journal of Laboratory and Clinical Medicine
`Arteriosclerosis and Thrombosis
`Pediatric Research
`Journal of Cell Biology
` American Journal of Pediatric Hematology Oncology
`Journal of Perinatology
`European Journal of Pathobiology
`Journal of Immunology
`European Journal of Hematology
`American Journal of Hematology
`Grant Reviews
`Member, NIH site visit team, U.C. Davis, 9/85.
`Member, NIH site visit team, N.H.L.B.I., La Jolla, CA. 03/01/89 – 03/03/89.
`Member, Special NIH study section Bacteriology / Mycology II, Boston, 08/21/90
`– 08/22/90.
`Member, N.H.L.B.I. Study Section Inflammatory and Vascular Disease,
`Bethesda, MD. 07/13 – 14/2001.
`NHLBI Special Study section for review of Sickle Cell Program project grant,
`Bethesda, MD. 4/23/2003.
`Ad Hoc program review committee, NHLBI, Baby HUG, 3/2005.
`NHLBI strategic planning committee May 11, 2006.
`Protocol review committee, Sickle Cell Clinical Research Network (NHLBI) 2007
`– present.
`Ad hoc Study section NIH for physician loan repayment awards 2008 – present.
`NHLBI Special study section K awards Jan 17/2008.
`T32/R25 Study Section NHLBI Jan 14, 2010.
`Comparative effectiveness Study section NHLBI Feb 2013.
`NHLBI Special emphasis panel 2016/10 ZRG1 VH-J (02) June 23, 2016 Vascular
`and Hematology.
`NHLBI Mentored Patient-Oriented Research Review Committee (K awards)
`October 27, 2016.
`Miscellaneous
`Co-chair Session on Granulocytes and Macrophages. AFCR, 05/01/1988.
`Abstract Selection, American Society of Hematology, Co/Chair Section on
`Granulocytes and Macrophages, American Society of Hematology Meetings,
`December 4, 1988.
`Moderator of Session on Receptor function in phagocytes, at the Phagocyte
`Workshop, AFCR, Washington D.C., April 28, 1989.
`
`

`

`Co-Chair, Session on Granulocytes and Macrophages, American Society of
`Hematology, December 1992.
`Abstract Selection-Moderator of Granulocytes Monocytes Session, American
`Society of Hematology meeting December 94.
`Invited Symposium Organizer, 9th International Congress for Biorheology, Big
`Sky Montana. Neutrophil Mechanics and Cell Motility, Chair of session. July
`1995.
`Guest Editor Symposium on Leukocytes, International Journal of Pediatric
`Hematology/Oncology Fall 1996.
`Invited Speaker, Biomedical Engineering Society Meetings, October 1996.
`Elected to the Board of Directors of the Medical Information Systems Physicians
`Association October 1996.
`Moderator, Session on Granulocytes and Monocytes, American Society for
`Hematology national meetings 12/97
`Visiting Professor, California Institute Of Technology 12/97.
`Abstract Selection/Moderator of session on Granulocytes and Monocytes,
`American Society for Hematology (ASH) National meeting, December 4-8,
`1998, Miami, FL.
`Coordinating Abstract Reviewer, session on Granulocytes and Monocytes,
`American Society of Hematology, December 1999, New Orleans, La.
`Moderator of session on Granulocytes and Monocytes, American Society for
`Hematology National meeting, December 4-8, 1999, New Orleans, La
`Chair, NIH Conference on Neutrophils and Sickle Cell Anemia, May 28, 1999,
`Bethesda, MD.
`Program Director, Medical Information Systems Physician Association (MISPA)
`International meeting, New York, NY, October 1999.
`Re-elected to the Board of Directors of the Medical Information Systems
`Physicians Association 10/99.
`Medical Director, Sickle Cell Camp Lazy W Ranch, San Juan Capistrano, CA,
`July 17-24, 1999.
`Chairman of Parvovirus B19 in Sickle Cell Disease protocol Committee, NHLBI,
`10/99 to 6/30/04.
`Co-Organizer, Thalassemia Standards of Care Conference, Double Tree Hotel,
`Pasadena Ca, June 3, 2000.
`President-elect Medical Information Systems Physician Association (MISPA)
`2001.
`Abstract reviewer, Hemoglobinopathies, American Society Hematology, 2001.
`Coordinating Reviewer, Hemoglobinopathies ASH 2002.
`Moderator of session on Hemoglobinopathies, excluding Thalassemia, (12/9/02),
`American Society for Hematology National Meeting, December 06-10, 2002,
`Philadelphia, PA.
`
`

`

`Moderator of Clinical Research session, 27th Annual Meeting of the National
`Sickle Cell Disease Program, April 19 2004, Los Angeles.
`Moderator of Basic Science Research session, 27th Annual Meeting of the
`National Sickle Cell Disease Program, 20 2004, Los Angeles.
`Awarded a “Lifetime Achievement Award” by the Sickle cell Foundation of
`California at the 50th anniversary celebration, November 15, 2007.
`H. Russell Smith Award for Innovation in Research, CHLA Saban Research
`Institute, July 14, 2009.
`Invited organizer NIH conference on Nutrition and Hemoglobinopathies
`Bethesda, August 21, 2010
`Abstract reviewer, Red Cell Disorders, American Society of Hematology National
`meeting 2011.
`Co-Chair, Advances in Treatment of Transfusional Iron Overload: New
`Opportunities for Better Patient Care Symposium, American Society of
`Pediatric Hematology-Oncology, New Orleans, LA, May 9, 2012.
`Invited Participant, US Sickle Cell Advisory Board, Sangart, Chicago, IL, June
`13-14, 2012.
`Co-Chair, Sickle Cell Disease and Integrative Physiology Approach Symposia,
`International Hemorheology meeting, Istanbul, Turkey, 2012.
`Coordinating reviewer Hemoglobinopathies session American Society for
`hematology national meeting Atlanta Dec 8-12, 2012.
`Moderator session on Hemoglobinopathies American Society for hematology
`national meeting Atlanta Dec 8-12, 2012.
`Moderator session on Hemoglobinopathies American Society for hematology
`national meeting New Orleans Dec 5-10, 2013.
`Invited Organizer, Sessions on Iron and BMT, TANDEM BMT meetings Honolulu
`Hawaii, Feb 2016
`
`
`F. Research Activities:
`Major Areas of Research Interest
`Role of inflammatory cells in promotion of vascular occlusion in sickle cell
`disease.
`Pathophysiology of sickle cell crisis, vasculopathy in sickle cell disease and the
`roll of autonomic dysfunction in sickle cell disease.
`Treatment of Thalassemia syndromes.
`Iron toxicity in Thalassemia and sickle cell disease.
`Polymorphonuclear Leukocyte physiology and its relation to human disease.
`Relation of blood rheology to blood flow and tissue oxygenation in sickle cell
`anemia.
`Role of autonomic dysfunction in genesis of sickle crisis.
`Role of pain and autonomic regulation in sickle cell disease.
`Pulmonary complications of sickle cell disease.
`
`

`

`Iron Toxicity in Thalassemia and sickle cell disease.
`Active Research Grants/Contracts
`Principal Investigator
`1. Multimodal biophysical biomarkers of vascular disease in hemoglobinopathies.
`Coates, Thomas D. (Lead PI) 1 U54 HL117718-01 (NHLBI) 04/01/2013 –
`03/31/2018 Excellence in Hemoglobinopathies Research Award
`(EHRA)
`$1,897,071 per year. Total award for $9,701,868 for 5 years.
`2. Phase III randomized prospective trial of Luspateracept ( ACE-536-B-THAL-001)
`for the treatment of transfusion dependent thalassemia. 6/6/2016 T Coates local
`PI (approx. $540,000 total costs) Celgene Corporation
`
`
`Co-Investigator
`1. Optimizing Tissue Iron Quantification at 3T, 1R01DK097115-01A1, NIH Wood,
`JC PI, Coates Co-I. 9/15/2013 – 08/31/2017, $268,575.
`
`
`Grants Pending:
`Principal Investigator:
`Co-investigator:
`1. Cerebrovascular reserve and white matter disease in patients with anemia
`R01 HL136484-01 MCH NIH. PI Wood, JC, Co-I Coates, TD
`Grants and contracts completed
`Principal Investigator
`1.
`Iron overload in Sickle Cell Disease, Coates, PI; ApoPharma, 1/1/06-1/1/07
`$160,000.
`2. Neutrophil Activation and Rheology in Sickle Cell Disease: Relationship to
`Vascular Occlusion, (Project 4) NIH 90/HL/15/B (04/01/93 t- 03/31/98)
`(04/01/98 to 03/31/03) Total Direct: $1,500,000.
`3. A Study of the Seroprevalence and Incidence of Parvovirus B-19 infection in
`Children’s with Sickle Cell Disease. (sub-contract of RFA NIH 90/HL/15B,
`National Chair T Coates) 10/01/99 to 03/31/03) Total Direct: $150,000.
`4. Comprehensive Hemophilia Center, Through Region IX (NIH) MCJ-062010-08
`(10/01/97 to 09/30/2001) and U27CCU – 913129-02 (09/30/97 to 09/29/2001)
`Total Direct: $800,000.
`5. Role of Granules and Organelles in Leukocyte Activation, NIH RO1 AI23547-11
`(12/01/84 to 11/30/99) Total Direct: $1,500,000 last 4 years.
`Intracellular calcium oscillations and their relation to neutrophil motility NIH 5P41
`RR01861/11 Subcontract:0013(USC) Biomedical Simulations resource.
`(9/30/92 to 11/30/05).
`
`6.
`
`

`

`8.
`
`7. Comprehensive Sickle Cell Center: Data Coordinating Core RFA NIH
`90/HL/15/B (01/04/93 to 03/31/98) Total Direct: $300,000.
`Iron overload in Sickle Cell Disease, Coates, PI; ApoPHarma, 1/1/06-1/1/07
`$160,000.
`9. Basic and Transitional Research Program (admin, impact of viscosity, scholar:
`three components listed below), NIH U54HL090511, 6/15/2008- 3/31/2012
`Total 4 yrs $2,483,000 PI T Coates
`10. Basic and Translational Research Program: Administration Component, NIH
`U54HL090511, 6/15/2008- 3/31/2012 Total $84,000 /yr PI Coates
`11. Basic and Translational Research Program: Scholar Component, NIH
`U54HL090511, 6/15/2008- 3/31/2012 Total $165,000 / year PI Coates
`12. Effect of viscosity on oxygen delivery in humans with sickle cell anemia, NIH
`U54HL090511, 20%, 6/15/2008- 3/31/2012 $366,997 /yr PI Coates
`13. Blood and transfusion safety CDC DD11-1108 Coates, Thomas D (PI)
`05/01/2012 – 04/30/2015, Centers for Disease Control $135,000 per year.
`Co-Investigator
`1. A Pilot Study of the Response of Oxidant-Stress Induced Injury and
`Mitochondrial Dysfunction Bio markers to Treatment with Iron Chelators: NHLBI:
`Thalassemia Clinical Network. Local PI: T. Coates. 7/1/2003-6/30/2005 Total
`Direct: (to be determined).
`2. ICL 670 MRI measurement of iron 109 sub Novartis Local PI: T. Coates ,I
`7/1/2003-6/30/2005 Total Direct: $100,000.
`3. Protein phosphatase 1 and neoplastic transformation NIH 1R01-CA54167
`(12/01/98 to 11/03/03) N. Berndt PI. Total Direct $1,087,500.
`4. Iron Overload in β Thalassemia and sickle cell disease: A Multi-center Study:
`RO1 DK057778-01 8/01/01-7/31/06, (NIH Through Oakland, PI E. Vichinsky) (PI
`local site T. Coates) – Total $19,540 CHLA site only
`5. Role of Placenta Growth Factor in Sickle ACS. NHLBI. RFA HL-04-015, P. Malik
`PI (TC CO-I 5%) (06/05 – 06/09 $2,400,000 ).
`6. Natural History of Hemoglobin E/β Thalassemia. NKH NL61186-01. 2/16/1999 to
`9/30/2003 (NIH through Children’s Hospital Oakland) local PI: T. Coates.
`Unable to determine amount.. accrual based.
`7. Primary prevention of Stroke in Sickle cell disease (STOP II) 2 UO1 HL52193-8
`Multi center trial to test the effect of transfusion on stroke. NHLBI R. Adams PI
`Multi Center Trial. local PI: T. Coates Total Direct: $21,500 /yr. CHLA site only.
`8. Neutrophil Function in Polynesian Children. NIH 11/1998 -11/2003) PI: Dr. Kyono
`in Honolulu Total Direct: $800,000
`9. General Clinical Research Center (GCRC) 5MO1 RR0043-38 Computer Data
`Analysis Core (Director), Children’s Hospital Los Angeles, (07/01/95 to 12/05)
`Total Direct: $300,000 /year
`10. Hemorheology Studies Related to In Vivo Blood Flow: USPHS, R37 HL15722
`(05/01/89 to 04/30/2004). PI: H. Meiselman, USC. Total direct $1,204,000
`
`

`

`11. Phase III Multicenter, Randomized, Double Blind Placebo-Controlled Study of
`CRL561 (Purified Poloxamer 188) in Patients with Sickle cell Disease in Active
`Vaso-Occlusive Crisis. (04/98 to 03/2001) CytRx Corporation. Total Direct:
`$35,000
`12. Phase I Multicenter Study of CRL561 (Purified Poloxamer 188) in Patients with
`Sickle cell Disease in Acute Chest Syndrome. (04/98 to 03/2001) CytRx
`Corporation. (Local PI, T. Coates) Total Direct: $15,000
`13. Clinical importance of treating iron overload in sickle cell disease. Novartis
`CICL670US30T 6/15/2008- 3/31/2010 Total $200,000
`14. Human Models Of Sickle Vascular Damage, NIH RO1-HL07180, 20% 7/1/2003-
`6/30/2008 Total Direct: $800,000 PI T Coates
`15. Southern California Comprehensive Thalassemia Center U27/CCU922106-01
`9/30/02-09/29/2007 Total Direct: $690,000
`16. Longitudinal study of cardiac iron and function in iron loaded patients on ICL670.
`Novartis. 10/04-9/2010 Total Direct: (Estimate Total $500,000)
`17. ICL 670 in Thalassemia. Randomized trial 107 Novartis Local PI: T. Coates :
`7/1/2003-6/30/2009 Total Direct: $419,000
`18. ICL 670 in Sickle Cell Disease 109 Novartis Local PI: T. Coates ,I 7/1/2003-
`6/30/2009 Total Direct: $500,000
`19. A 5 year observational study of children aged 2 to less than 6 years at
`enrollment with transfusional hemosiderosis treated with deferasirox,
`CICIL670A2411, 9/2009-8/2014.
`20. Comparative Effectiveness of strategies to improve iron, Neufeld, PI, Total
`Direct: $5760, 08/15/2011 – 06/30/2012.
`21. Iron-mediated vascular disease in sickle cell disease, J. Wood, PI.
`1RC1HL099412-01, 9/30/09-8/31/12, $1,000,000 total direct.
`22. Cardiac Iron T2* in thalassemia. 1 RO1 HL075592-01 J. Wood PI, 7/01/04-
`6/31/08 Total Direct: $1,400,000.
`23. Pituitary iron and function in thalassemia major, J. Wood, PI, 2008-2011.
`24. Pancreatic iron and glucose tolerance in thalassemia, 8/01/07-8/30/08, J Wood
`PI Cooley’s anemia foundation, $50,000.
`25. Silent Cerebral Infarct Multi-Center Clinical Trial, NHLBI Local PI T Coates Total
`Direct: $156,000 / yr + (accrual dependent). Safety and efficacy of sodium
`nitrite injection for the treatment of vaso-occlusive crisis associated with sickle
`cell disease, Hope Pharma, SN-SC-02091, 5% 1/1/2010 to 1/1/2013, $10,000
`approx.
`26. Research Initiatives for the Prevention of the Complications of Thalassemia,
`CDC, U27/CCU922106-01 $180,000 per year 9/30/2007 – 9/29/2012.
`27. CDC RUSH thalassemia and sickle cell disease, CDC cooperative agreement,
`Total $263,500 per year 2/1/2010-1/31/2012.
`28. Thalassemia Clinical Research Network, 1 UO1 HL65233 (NIH through
`Oakland). Local PI T. Coates Total $50,000 CHLA site only.
`
`

`

`4.
`
`5.
`
`8.
`
`6.
`7.
`
`29. Hemoglobinopathy follow-up program, Contract State of California, 2009,
`$50,000 / yr.
`30. Accrual based Hemoglobinopathies Surveillance, Health Promotion, and
`Laboratory Capacity Demonstration Project (Module A: SickleCell/Module B:
`Thalassemia) CDC-RFA-DD12-1206, Coates MD, Thomas D. (Co-PI)
`09/01/2012-08/30/2014 California Department of Health,
` $78,582 per year.
`31. Gene Therapy in Sickle Cell Disease, #DR1-01452, CIRM, D Kohn PI, Coates
`Co-PI (20%), $1,000,000 per year 03/01/2010 – 02/28/2014. Sub contract to
`CHLA about $180,000 per year.
`G. Invited Presentations
`2.
`Pediatric Grand Rounds, CHLA Los Angles, September 1985.
`3.
`Hematology/Oncology Grand Rounds, Clinical Neutrophil Disorders,
`02/13/86.
`Los Angeles County Disorders of Neutrophil Dysfunction, Allergy,
`Immunology seminar, 02/27/86.
`Studies in Neutrophil Function: Immunology Research Conference, at
`Children’s Hospital of Los Angeles, 03/26/86.
`Studies in Neutrophil Activation, CHLA Research Seminar, 05/27/86.
`Nutritional Support in Children with Cancer, Research Seminar, Division of
`Pediatric Gastroenterology, 05/29/86.
`Neutrophil Disorders in Children, Ventura County Medical Pediatric Society,
`06/03/86.
`Neutrophil Physiology, Hematology Fellows, 07/02/86.
`9.
`10. Clinical Disorders in Neutrophil Function, Hematology Fellows, 07/03/86.
`11. Neutrophil Activation / Summer Oncology Students, 07/15/86.
`12.
`Joint Conference of Neonatal/Pediatric Pulmonary Div. and Hematology/
`Oncology Research Lecture (CHLA). Temperature Ramps and Fluorescence
`Studies, 09/08/86.
`Joint Conference of Neonatal/Pediatric Pulmonary Div. and Hematology/
`Oncology Research Lecture (CHLA). Neutrophils, 11/10/86.
`Joint Conference of Neonatal/Pediatric Pulmonary Div. and Hematology/
`Oncology Research Lecture (CHLA). Imaging Systems, 01/17/87.
`15. Clinical Disorders of Neutrophil Function, CHLA, House Staff 01/27/87.
`16. Nutritional support of Cancer Patients in Oncology Patients, Children’s
`Hospital of Los Angeles nursing staff, 03/17/87.
`17. Neutrophils and the Child with Recurrent Infections, 05/07/87, Postgraduate
`Pediatric Course.
`18. Regulation of Neutrophil Activation. The University of Southern California,
`Department of Pathology, 05/21/87.
`
`13.
`
`14.
`
`

`

`19. Nursing Recognition of Complications of Oncology Treatment / Tumor Lysis
`Syndrome, Children’s Hospital of Los Angeles, Nursing Staff, 4 West,
`06/26/87.
`20. Physiological Aspects of White Blood Cells, Children’s Hospital of Los
`Angeles, Hematology Fellows, 07/02/87.
`21. Clinical Disorders of PMN Functions, Children’s Hospital of Los Angeles,
`07/03/87.
`22. Pathological Aspects of White Blood Cells, Children’s Hospital of Los
`Angeles, Hematology Fellows, 07/06/87.
`23. Clinical Disorders of Neutrophil Function, Children’s Hospital of Los Angeles,
`07/08/87.
`24. Computers in Research, Children’s Hospital of Los Angeles, 07/13/87.
`25.
`The Nature and Function of Granulocytes, Children’s Hospital of Los Angeles,
`Summer Oncology Fellows, 07/14/87.
`26. White Cell Activation, Children’s Hospital of Los Angeles, Allergy/
`Immunology Group, 08/11/87.
`27. Newborn Hematology / Granulocyte Aspects, USC, Grand Rounds Pediatric
`Pavilion, 03/08/88.
`28. Up/date on Fluidity Studies, Research Group Lecture, CHLA, 03/28/88.
`29. Regulation of Membrane Function in Human Neutrophils, USC toxicology
`graduate students seminar, 04/21/88.
`30. Chronic Granulomatous Disease, Children’s Hospital of Los Angeles,
`members of the Allergy Clinical Immunology Division, 05/31/88.
`31. Disorders of Granulocytes and Monocytes, Children’s Hospital of Los
`Angeles, Hematology Fellows, 07/06/88.
`32. Disorders of Granulocytes, Beverly Hospital, pediatric and family practice
`physicians and nurses, 07/21/88.
`33. White Cells, Children’s Hospital of Los Angeles, 4/West,
`34.
`Teaching Core Program, 10/19/88.
`35. Anemia in Childhood, Memorial Medical Center of Long Beach, family
`practice residents and faculty, 11/07/88.
`36. Child with Recurrent Infections, Children’s Hospital of Los Angeles, Division
`of Hematology/Oncology, 4 West Teaching Core Program, 11/16/88.
`Issues in the Use of TPN in the Child with Cancer, Children’s Hospital Los
`Angeles, Conference for Nurses, 11/30/89.
`38. Current Status of CGD / Clinical Aspects, Children’s Hospital of Los Angeles,
`Division of Hematology/Oncology Grand Rounds, 2/23/89.
`39. Sepsis: Overview of the Immune System, Predisposing Factors, Early Clinical
`Signs and the Septic Work/up. Nursing Care of the Hospitalized Child, The
`San Francisco Conference, Contemporary Forums, 2/8/89.
`40. Child with Recurrent Infections. 4 West Teaching Core Program, Children’s
`Hospital of Los Angeles, 3/22/89.
`
`37.
`
`

`

`47.
`
`41. Chronic Granulomatous Disease. Pediatric Grand Rounds, Olive View
`Medical Center, 4/12/89.
`42. Neutrophil dysfunction. 4 West Residents, Children’s Hospital of Los Angeles,
`5/31/89.
`43. Studies on a new chemotaxis disorder. Children’s Hospital of Los Angeles,
`Cell Biology Group, Monday Conference, 4/89.
`44. Child with recurrent infections. 4/West (Residents), Children’s Hospital of Los
`Angeles, 6/28/89.
`45. Nutritional Support in Pediatric Oncology. 4/West (Residents), Children’s
`Hospital Los Angeles, 7/5/89
`46. Disorders of Granulocytes & Monocytes. Children’s Hospital of Los Angeles,
`Fellows Orientation Program, 7/7/89.
`"Actin Dysfunction" to the Immunology Research Group. Children’s Hospital
`of Los Angeles, 7/19/89.
`48. Computer Use In Medicine. Children’s Hospital of Los Angeles, Fellows
`Orientation Program, 7/19/89.
`49. Computer Enhanced Imaging and Fluorescent Probes. Children’s Hospital of
`Los Angeles, Fellows Orientation Program, 7/28/89.
`50. Research update on chronic granulomatous disease: "Disorders of
`Granulocytes". University of Nevada,